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Exposure of cells and organisms to stressors might result in epigenetic changes. Here it is shown that investigation of DNA
methylation using pyrosequencing is an alternative for in vitro and in vivo toxicological testing of epigenetic effects induced
by chemicals and drugs. An in vitro evaluation of global and CpG site specific DNA methylation upon treatment of cells with
chemicals/drugsisshown.BisulfitegenomicsequencingofmethylationcontrolsshowedhighmethylationofLINE1inmethylation
positive control and low methylation in the negative controls. The CpG sites within the LINE1 element are methylated at different
levels. In vitro cell cultures show a methylation level ranging from 56% to 49%. Cultures of drug resistant tumor cells show
significant hypomethylation as compared with the originating nonresistant tumor cells. The in vitro testing of epigenetically
active chemicals (5-methyl-2’-deoxycytidine and trichostatin A) revealed a significant change of LINE1 methylation status upon
treatment, while specific CpG sites were more prone to demethylation than others (focal methylation). In conclusion, DNA
methylation using pyrosequencing might be used not only for testing epigenetic toxins/drugs but also in risk assessment of drugs,
food, and environmental relevant pollutants.
1. Introduction
Epigenetic factors such as DNA methylation, histone modifi-
cations, and microRNAs are able to regulate gene expression
and genomic stability [1–3]. CG dinucleotides have unic
f ea t u r ei nth em a m m al ia ng e n o m e :th eyca na s soc ia t ei nCG s
cluster regions termed CpG islands [4]. DNA methylation
occurs in CpG islands that could be related to transcriptional
silencing of genes. Thus, active gens show low methyla-
t i o ni nt h eg e n ep r o m o t e r - a s s o c i a t e dC p Gi s l a n d s ,w h i l e
in downstream-transcribed gene regions and in repetitive
regionssuch asLINEs andSINEs, hypermethylationisfound
[4–8]. DNA methylation pattern is maintained due to enzy-
matic activity: DNA methyltransferase (DNMT) family con-
trols de novo and maintenance DNA methylation. Therefore,
it is possible to modify the DNA methylation status of genes
using agents that hinder the function of DNA methylation
enzymes [9].
Retrotransposons are mobile elements with the property
of moving within a gene via a copy and paste mechanism.
Thus, they are responsible for creating genetic variation but
also might be the reason for creation disease-causing muta-
tions within the human genome (i.e., insertional mutagen-
esis, recombination, retrotransposition-mediated and gene
conversion-mediated deletion, and 3
򸀠 transduction). Active
retrotransposable elements include long interspersed ele-
ments (LINEs) and short interspersed elements (SINEs)
while approximately 0.27% of all human disease mutations
are attributable to retrotransposable elements [10]. LINE1
retrotransposons are present in the human genome (esti-
mated 500,000 copies/genome); they disseminate through
RNAsequencesinDNAsequencesafterreversetranscription
and are then integrated into new genomic loci such as
nearby genes. Thus, they are able to epigenetically disrupt
t h et r a n s c r i p t o m ea n dc o n t r i b u t et op r o c e s s e sr e l a t e dt o
tumorigenesis [11].2 BioMed Research International
A large body of toxicological evidence shows that many
substances could have an impact on human’s health without
clearsignsofacuteorimmediatetoxicity.Inchronicexposure
to damaging chemicals (long-term toxicity), it is often found
thatthechemicalsinducechangesintheDNAsequence,thus
resulting in DNA damage and mutagenesis. Nevertheless,
epigenetic research shows that toxic chemicals could also
modify the DNA function without changing the sequence,
d u et o ,f o re x a m p l e ,c h a n g i n gt h es t a t eo fD N Am e t h y l a t i o n ,
thus inducing deregulated gene expression and genomic
instability [1–3, 9]. Thus DNA methylation might play an
integral role in toxicity through the hypomethylation of
repetitive DNA elements that impacts chromosomal and
transcriptional stability of the genome and also as a result of
focalhypermethylation,thusresultinginepigeneticsilencing
of gene expression (DNA methylation and gene expression
are inversely correlated) [12, 13].
Long-termtoxicologicaldamagecouldbecausedwithout
changing the DNA sequence, thus having important impli-
cations on the safety assessment for chemicals, drugs, and
food [9]. Epigenetic alterations may be early indicators of
genotoxic and nongenotoxic carcinogenic exposure and thus
used as biomarkers in the assessment of the carcinogenic
potential of environmental chemical and physical agents and
m i g h tb eu s e di nc a n c e rr i s ka s s e s s m e n t[ 14]. For example,
environmental relevant chemicals such as arsenic, cadmium,
a ndb is p heno lAha v eep ig eneticmod ula tio np r o perty([3,15,
16] ) b u ta l s om i x t u r e so fb e n z e n e ,h y d r o q u i n o n e ,s t y r e n e ,
carbon tetrachloride, and trichloroethylene [17].
All major human cancers have a large number of
genetic alterations and epigenetic abnormalities that might
be used as biomarkers for the molecular diagnosis of cancer.
The genome-wide loss of methylation at CpG sites of the
promoter is a common epigenetic event in malignancies
and may play a role in the process of carcinogenesis [14],
while changes in promoter DNA methylation and asso-
ciated gene silencing might be used for cancer therapy
(e.g., decitabine and azacitidine) [18]. Thus, investigation of
chemical induced changes in DNA methylation status could
represent an important indicator for chemical induced risk
assessment.
Inthispaperitisshownthatpyrosequencingisapplicable
in toxicity tests to investigate the modification in DNA
m e t h y l a t i o nu p o ne x p o s u r et oc h e m i c a l sin vitro.P y r o s e -
quencing could be adapted to provide accurate quantifiable
data and detailed profiles of DNA methylation patterns
underlying, for example, cell cycle regulation, differential
gene expression, and epigenetic effects.
2. Material and Methods
Pyrosequencing is a quantitative sequence-based detection
technology, adaptable for exploratory and testing work in
t o x i c o l o g ya n da l s oi np h a r m a c o l o g i c a la p p r o a c h e s .M a n y
ready designed assays (PyroMark CpG Assays) are available
for pyrosequencing analysis; for example, more than 84,000
assays are available for gene-specific CpG islands including
the mouse and rat genomes (Qiagen, Germany; EpigenDX,
USA). These assays are created using algorithms that provide
specific quantification of CpG methylation.
Using pyrosequencing for the investigation of DNA
methylation has been proofed as highly reproducible and
highly sensitive in praxis. Companies are offering to users
the possibility of buying ready to use kits for pyrosequencing
especially diagnostic relevant biomarkers such as KRAS,
MGMT, p16, LINE1, MLH1, and BRAF (Qiagen, Germany;
EpigenDX, USA). Although the number of available pre-
designed ready to buy DNA methylation assays (e.g., Pyro-
Mark CpG Assays) has considerably increased in the market,
the researcher today might be put in the position that there
a r en oa s s a y sa v a i l a b l ef o rs p e c i fi cb i o m a r k e r s .Th u s ,i ti s
possible to create self-designed assays using commercial
software (PSQ assay design) or freely available software
(Primer3).
2.1. Cell Culture. Normal human dermal fibroblasts (NHDF)
were provided from PromoCell, Germany. The cells were iso-
lated from normal human foreskin from a 10-year old donor
and cryopreserved at passage 2 (P2) using serum-free freez-
ingmedium,Cryo-SFM(PromoCell,Germany).Thecultures
were maintained in the incubator at 37
∘C, 5% CO2.Th e
cells were split once they have reached 80–95% confluence
by using Trypsin-EDTA (0.025%) (PAA, Germany). After
collectingthedetachedcellsinTrypsininhibitor(PromoCell,
Germany) the cells were maintained in cell culture dishes
(NUC, Germany). The fibroblast cultures were maintained
in serum-free fibroblast culture medium, without phenol
red, supplemented with “Supplement Mix” (basic fibroblast
growth factor 1ng/mL and insulin 5ng/mL) (PromoCell,
Germany) as well as antibiotics: penicillin/streptomycin
(PAA, Germany).
HACAT cells (DKFZ, Germany) are in vitro sponta-
neously transformed keratinocytes derived from histological
normal skin that grows in DMEM medium (high glu-
cose) supplemented with 2mM L-glutamine (PAA) and 10%
fetal calf serum (PAA, Germany) as well as antibiotics:
penicillin/streptomycin (PAA, Germany). The cultures were
maintained at 37
∘Cw i t h5 %C O 2 and splitted as necessary if
they reached 80–95% confluence [19].
2.2. 5-Methyl-2
򸀠-deoxycytidine and Trichostatin A Treatment
(A + T2) of HACAT Cells. HACAT cells were plated in
10cm
2 culture dishes at 50% confluence and were left over
night for attachment. They were treated (𝑛=6 )w i t ht h e
demethylating agent 5-aza-2
򸀠-deoxycytidine (5-Aza) and the
histone deacetylase inhibitor trichostatin A (TSA) (Sigma,
Germany). The treatment conditions were done with either
the demethylating agent 5-aza-2
򸀠-deoxycytidine (1𝜇Mf o r
72h)orthehistonedeacetylaseinhibitortrichostatinA(1𝜇M
for 36h).
2.3. Glioma Cell Lines LNT-229, LN-308, and LN-18. All
glioblastoma cell lines were grown under standard condition
and as elsewhere described [20]. Dulbecco’s modified Eagle’s
medium(DMEM)wasusedasbasalmedium.10%(v/v)heat-
inactivated fetal bovine serum (FCS) and 1% (v/v) penicillinBioMed Research International 3
G/streptomycin were added to the medium and cells were
incubated at 37
∘C in a humidified atmosphere containing 5%
CO2. The cell culture of glioma cell lines and temozolomide
(TMZ) resistant cells were elsewhere described [20]. Cell
pellets from drug sensitive and drug resistant cell lines were
providedfornucleicacidextractionandpyrosequencing[20].
2.4. Kidney Carcinoma CKA-CA6 Cells and Human Embry-
onic Kidney HEK293 Cells. The DNA was kindly provided
by PD Dr. Csaba Mahotka (Pathology, HH University
D¨ usseldorf).TheDNAextractionwasdoneusingtheQiagen
DNA extraction kit and the company provided protocol. The
cells were grown using standard cell culture procedures.
2.5. Nucleic Acids Extraction and Bisulfite Conversion of
the Genomic DNA. Nucleic acid extraction was performed
as reported elsewhere [21] using ultracentrifugation and
caesiumchloridemethodfollowedbythephenol/chloroform
purification or using the DNA extraction kit from Qiagen,
Germany, using the providers protocol. One microgram
of genomic DNA was further subject of bisulphite trans-
formation using the EZ DNA Methylation Gold Kit (Hiss
Diagnostics,Germany)inordertobeusedinpyrosequencing
reactions.
2.6. Primer Design. Long interspersed nuclear element 1
(LINE1 or L1) sequences are highly repeated human retro-
transposonsequencesandconstituteabout17%ofthehuman
genome. DNA methylation within the promoter region of
human LINE1 elements is important for maintaining tran-
scriptional inactivation and for inhibiting transposition [22].
Genome-wide losses of DNA methylation within the pro-
moter region of human LINE1 elements have been regarded
as a common epigenetic event in malignancies and may
play crucial roles in carcinogenesis [11].This methylation
assay amplifies a region of the LINE1 element and serves
as a marker for global methylation. PyroMark LINE1 from
Qiagen, Germany, has been used following the company
recommendations and elsewhere described [20]. CpG sites
a r el o c a t e di np o s i t i o n s3 3 1t o3 0 5o fL I N E 1( G e n B a n k
accession number X58075).
Self-designed assays were obtained using the PSQ assay
design. The sequence of LINE1 element was obtained using
RefSeq (GenBank accession number X58075). The location
of each primer combination is shown in Figure 1.W i t ht h e
helpofMicrosoftWord(Microsoft,USA)theLINE1sequence
was in silico bisulfite converted (all CG => YG; all C => T)
and pasted in the primer design software. The result of the
primer design is shown in Tables 1 and 2. The LINE1 CpG1-
6 is located at the beginning of the sequence (X58075) and
is spanned over 6CpG sites while LINE1 CpG7-14 is located
after LINE1 CpG1-6 and is spanned over 8CpG sites.
2.7. Pyrosequencing. For pyrosequencing the PyroMark
LINE1 kit (Qiagen, Germany) was used following the
company recommendations. In brief, each PCR mix con-
tained 1× PCR buffer, 1.5mmol/L of MgCl2 (final con-
centration) (Qiagen), 0.2mol/L of each dNTP (Biobudget,
(1)
(2)
(3)
Location of the sequences analyzed for total methylation (LINE1: ×58075):
PSQ assay design LINE1 repetitive element
(1) LINE1CpG1-6 (self-designed)
(2) LINE1CpG7-14 (self-designed)
(3) LINE1Qiagen (provided from Qiagen)
Figure 1: Long interspersed nuclear element 1 (LINE1 or L1)
sequences are highly repeated human retrotransposon sequences.
Here, the LINE1 GenBank accession number X58075 is shown
after in silico bisulphite conversion; the location of the investigated
primers are shown.
Germany), 1𝜇L of forward and reverse primer (10pmol/L of
e a c hP C Rp r i m e r ) ,2Uo fH o t S t a rT a qP o l y m e r a s e( Q i a g e n ) ,
and 2𝜇L of bisulfite treated template DNA in a total volume
of 50𝜇L.
PCRconditionswereasfollows:initialdenaturingat95
∘C
f o r1 5m i n u t e s ;4 5c y c l e so f9 5
∘C for 20 seconds, 50
∘Cf o r2 0
seconds, and 72
∘C for 20 seconds; and final extension at 72
∘C
for 5 minutes giving an amplicon length of 146bp. The PCR
product was checked by 1% agarose gel electrophoresis (data
not shown). The biotinylated PCR product was purified to
single-stranded DNA to be the template in a pyrosequencing
reaction, as recommended by the manufacturer using the
Pyrosequencing Vacuum Prep Tool (Qiagen, Germany).
Forty microliters of biotinylated PCR product were
immobilized on streptavidin coated sepharose beads. There-
after, the sepharose beads containing the immobilized PCR
product were purified, washed, denatured using a 0.2M
NaOH solution, and washed again. Then, 0.3𝜇Mp y r o s e -
quencingprimerwasannealedtothepurifiedsingle-stranded
PCR product and pyrosequencing was performed by Pyro-
Mark Q24 (Qiagen, Germany). The sequence to analyze was
TTYGTGGTGYGTYGTTTwhilethedispensationorderwas
GCTCGTGTAGTCAGTCG [20].
Similarlyitwasproceededwiththeself-designedprimers
LINE1 CpG1-6 and LINE1 CpG7-14. Primers were ordered
at Eurofins (Germany) and reassembled as recommended
by the provider. For PCR reaction the HotStar Taq Poly-
merase from Qiagen was used. PCR conditions: 95
∘C-5min.
(1 cycle); 95
∘C-1min., 57
∘C-1min., 72
∘C-1min. (50 cycles);
72
∘C-5min. (1 cycle); 4
∘C ∞.Th ea s s a y sw e r ep r o o f e du s i n g4 BioMed Research International
Table 1: Self-designed pyrosequencing assays using PSQ assay design are shown. Primer score represents the probable quality of the primer
combinations (min. 0-> max. 100, color score: blue > yellow > orange > red); F1: forward primer; R1: reverse primer (biotinylated); S1:
sequencing primer (LINE1 CG1-6).
(a)
Primer set 1 Score: 76
General warnings
(b)
⇀ F1 GGGAGGAGTTAAGATGGT
= R1 ATAAACCCCATACCTCAAA
→ S1 GGGAGGAGTTAAGATGGT
(c)
PCR product Forward PCR primer, F1 Reverse PCR primer, R1 Sequencing primer, S1
Length, bp 109 18 19 18
Position, 5
򸀠-3
򸀠 3-20 111-93 3-20
Warnings
Tm,
∘C 60.2 60.9 53.1
% GC 33.0 50.0 36.8 50.0
Sequence to
analyze
YGAATAGGAA TAGTTTYGGT TTATAGTTTT TAGYGTGAGY GAYGTAGAAG AYGGGTGATT TTTGTATTTT TATTTGA
Table 2: Self-designed pyrosequencing assays using PSQ assay design are shown. Primer score represents the probable quality of the primer
combinations (min. 0->max. 100, color score: blue > yellow > orange > red); F1: forward primer; R1: reverse primer (biotinylated); S1:
sequencing primer (LINE1 CG7-14).
(a)
Primer set 1 Score: 81
General warnings
(b)
⇀ F1 GGTTTATTTTATTAGGGAGTGTTA
= R1 AAAAAAAAACTCCCTAACC
→ S1 AGGGAGTGTTAGATAGTGG
(c)
PCR product Forward PCR primer, F1 Reverse PCR primer, R1 Sequencing primer, S1
Length, bp 127 24 19 19
Position,
5
򸀠-3
򸀠 105-128 231-213 118-136
Warnings
Tm,
∘C 61.9 59.3 50.8
% GC 37.0 29.2 31.6 47.4
Sequence to
analyze
GYGTAGGTTA TTGTGTGYGY GTATYGTGYG YGAGTYGAAG TAGGGYGAGG TATTGTTTTA TTTGGGAAG
human methylation positive and negative controls as seen in
Figure 2 (ordered at EpigenDX, USA). The pyrosequencing
w a sd o n ea sr e c o m m e n d e db yt h ep r o v i d e ru s i n gt h eP y r o -
Gold Reagents 5 × 24 (Qiagen, Germany) and the PyroMark
Q24 Qiagen (Germany) and as described in detail above.
2.8. Statistics. Statistical analysis was done comparing con-
trol versus each condition while Student’s t-test was applied
where
∗𝑃 < 0.05.
3. Results
3.1. The Setup and the Quality Control of a DNA Methylation
Pyrosequencing Assay. To make sure that a specific DNA
methylation assay functions in a given laboratory condition
t h em e t h y l a t i o nP C Rr e a c t i o nf o l l o w e db yp y r o s e q u e n c i n g
should be tested. Known methylation status DNA samples
s u c ha sp o s i t i v ea n dn e g a t i v em e t h y l a t i o nc o n t r o l sa r eu s e d .
They are available for purchase at many providers (e.g.,BioMed Research International 5
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Figure 2: Human methylation positive and negative controls (EpigenDX, USA) and PyroMark LINE1 kit (Qiagen, Germany).
EpigenDX, USA; Millipore, Germany) while mouse and rat
methylation controls are available as well. For this paper
are shown the results obtained with the human methylation
positive and negative controls bought at EpigenDX, USA
(Figure 2) and PyroMark LINE1 kit (Qiagen, Germany).
As described in the Material and Methods, for each test
reaction was used 200ng bisulphite transformed DNA for
(Figure 2 from (a) to (c))(1)methylationpositivecontrol;(2)
methylation negative control; (3) PCR negative control. The
establishment of the PCR negative control is very important
in order to check for (i) the contamination of the PCR
reaction, (ii) specificity of the primers, and (iii) size of the
PCR product. The PCR reaction was assembled as described
at the Material and Methods. After quality check on 1-2%
agarose gel (showing one clear PCR band) the PCR product
is purified with the Pyrosequencing Vacuum Prep Tool
(Qiagen, Germany) and proceeded with the pyrosequencing.
Typical good functioning pyrosequencing assay is shown
in Figure 2 (PyroMark LINE1 kit (Qiagen, Germany)). In
this case, the LINE1 sequence that was assessed by pyrose-
quencing has three CpG sites (see location in Figure 1). Over
each of the CpG site the found methylation level and the
qualityoftheobtainedresult(red=badquality,yellow=pass
quality, and blue = good quality) are shown. The pyrogram
s h o w si na d d i t i o nt h ew e l la n a l y z e da n dt h es e q u e n c et o
analyze. Furthermore, on the 𝑥-axis the nucleotides injected
b yt h ep y r o s e q u e n c e ra r es h o w nw h i l eo nt h e𝑦-axis the
luminescence detected by the LCD camera is shown.
In brief, in the shown pyrograms (Figure 2), the “E”
represents the moment when the enzyme was add to the
reaction followed by the substrate “S” that is documented
by a small spike. The pyrosequencer added a “G” that is not
present in the sequence (as in build reaction control); thus,
no spike was observed. Then the nucleotide “C” is added
to the reaction that represents the bisulphite transformation
control;inthiscasethebisulphitetransformationiscomplete
because no signal was detected by the pyrosequencer. The
actual sequence to analyze starts with a TT (that is double as
highasthesingleT)followedbyourmethylatedcytosinehere
markedwithY.Thepercentagesformethylationaretheresult
of the calculated ratio: thymine versus methylated cytosine.
The pyrosequencing continues with adding one by one the
nucleotides (here: G, T, GG etc.); if the nucleotide fits the
sequence a light signal is detected, if not no light signal is
detected.
In the methylation positive control it is shown that each
of the CpG sites has a high level of methylation, for example,
CG1 = 86%; CG2 = 71%; CG3 = 77%. In the methylation
negative control it is shown that each of the CpG sites has
a low level of methylation, for example, CG1 = 2%; CG2
=2 % ;C G 3=2 % .I fo n ec o m p a r e si nt h ep y r o g r a mt h e
spike present for the detection of the methylated cytosine in
the methylation negative control does not practically exist.
Furthermore, the PCR negative controls show no specific
spikes whatsoever of the nucleotides are injected in the
pyrosequencing reaction; thus, this pyrosequencing assay is
specific.
3.2. Different Cell Lines Show Different Methylation Status of
the LINE1 Element. Well-established cell lines were inves-
tigated for their intrinsic methylation level of the LINE1
element. In Figure 3, from (a) to (d), the pyrosequencing of
LINE1 element (Qiagen, Germany), a kidney carcinoma cell
line is shown (CKA-CA6), followed by human embryonic
kidney cells (HEK293), spontaneously immortalized human
keratinocytes (HACAT), and primary in vitro cultures of
normal human dermal fibroblasts (NHDF). The three inves-
tigated CpG sites show different levels of methylation in each6 BioMed Research International
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Figure3:Establishedtumor,nontumor,andprimarycelllinesinvestigatedfortheirintrinsicmethylationleveloftheLINE1element(Qiagen,
Germany): CKA-CA6 kidney carcinoma; HEK293 human embryonic kidney cells, spontaneously immortalized human keratinocytes
(HACAT), and primary in vitro cultures of normal human dermal fibroblasts (NHDF).
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Figure 4: Quantitation of intrinsic methylation level of the LINE1
element (Qiagen, Germany) in established tumor, nontumor, and
primary cell lines using several measurement replicates (𝑛=3 –6)
and the correspondent methylation controls (Student’s t-test,
∗𝑃 <
0.05).
cell line investigated. Also the methylation level was slightly
different in each cell line (Figure 4). The highest level of
methylationwasfoundforNHDFthatwasabout56%(𝑛=5 )
followed by 53% for HEK293 (𝑛=3 ), 51% for CKA-CA
(𝑛=3 ), and 49% for HACAT cells (𝑛=5 ). The measured
methylation value of methylation positive control was 79%
while for methylation negative control was 3%.
3.3.DrugSensitiveandDrugResistantGliomaCellLinesShow
Different Methylation Status of the LINE1 Element. Three
glioma cell lines were investigated for the methylation level
of LINE1 element as shown in Figure 5 from (a) to (d) for
LNT 229, LN 18, and LNT 308. The LINE1 methylation levels
(Qiagen, Germany) varied dramatically between the three
cell lines (Figure 6); the highest methylation was observed
in LNT 308 cells followed by LNT 229 and LN 18. In the
temozolomide resistant strains of same cell lines that were
obtained with treatment of increasing concentrations of the
drug, a decrease in the global methylation was observed, as
exemplarilydepictedforLNT308P(drugsensitive)andLNT
308R (drug resistant) (Figure 5(d)). Overall, the decrease in
globalmethylationwassignificantforLN18RandLNT308R
but not for LNT 229P (Student’s t-test,
∗𝑃 <0 . 0 5 ). This is an
indication not only that genes responsible for drug resistance
m i g h tb ea c t i v a t e db u ta l s ot h a tL I N E 1e l e m e n tm i g h tp l a y
an important role in the temozolomide drug resistance of
glioblastoma [20].
3.4. The Use of Self-Designed Pyrosequencing Assays in
the Evaluation the Modifications in DNA Methylation of
Epigenetic Regulating Chemicals/Drugs. Here the similarity
betweenthecommercialavailableLINE1elementkit(Qiagen,
Germany) and the self-designed assays (PSQ primer design,
Qiagen, Germany) was investigated (Figure 1 and Tables
1 and 2). HACAT cells were treated in vitro with DNA
demethylating agent 5-aza-2
򸀠-deoxycytidine (A) (1𝜇Mf o r
72h)andthehistonedeacetylaseinhibitortrichostatinA(T2)
(1𝜇Mf o r3 6h )a ss h o w ni nt h eM a t e r i a la n dM e t h o d s .Th e
results obtained in the pyrosequencing of LINE1 element kit
(Qiagen, Germany) are shown in Figure 7.
Observe that in the HACAT control cultures the methy-
lation level of each CpG site was 53%, 59%, and 63%,BioMed Research International 7
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Figure 5: Glioma cell lines were investigated for the methylation level of LINE1 element (Qiagen, Germany) for LNT 229, LN 18, and LNT
308.Temozolomideresistantstrainsofsamecelllinesthatwereobtainedwithtreatmentofincreasingconcentrationsofthedrug;exemplarily
depicted is LNT 308P (drug sensitive) and LNT 308R (drug resistant).
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Figure 6: Quantitation of intrinsic methylation level of the LINE1
element (Qiagen, Germany) in Temozolomide sensitive and resis-
tantgliomacelllinesusingseveralmeasurementreplicates(𝑛=3 –6)
and the correspondent methylation controls (Student’s t-test,
∗𝑃 <
0.05).
levels that decreased significantly (Student’s t-test,
∗𝑃 <
0.05) in HACAT A + T2 treated cells to 36%, 40%, and
42%. The total methylation of the 3CpG sites decreased
significantly (Student’s t-test,
∗𝑃 < 0.05)H A C A TA+
T 2t r e a t e dc e l l s ;h o w e v e rt h ed e c r e a s ew a sn o ta sh i g ha s
compared to the methylation positive and negative controls.
Also the significant (Student’s t-test,
∗𝑃 < 0.05)d e c r e a s e
in methylation HACAT A + T2 treated cells was identified
in each of the CpG sites of the LINE1 element kit (Qiagen,
Germany).
Similar results were obtained with the self-designed
assays (PSQ primer design, Qiagen, Germany) (Figure 1 and
Tables 1 and 2). The pyrosequencing assay Line1 CpG1-6
s p a n n e do v e r5 C p Gs i t e sl o c a t e da tt h eb e g i n n i n go ft h e
LINE1 element. As seen with previous assay the significant
decrease in total methylation (over all 5CpG sites) was
documented in Figure 8(a);h o w e v e re a c hC p Gs i t es h o w e d
decreased methylation level that was at least as strong as
observed for the pyrosequencing with the LINE1 element
kit from Qiagen, Germany. Nevertheless the decrease in
the LINE1 methylation was different in the CpG site; a
fact that might underline that specific CpG sites could be
preferentiallytargetedbytheepigeneticregulators(chemicals
and drugs).
The pyrosequencing assay Line1 CpG7-14 spanned over
8CpG sites located at the beginning of the LINE1 element,
after Line1 CpG1-6 but before the primers of LINE1 element
kit, Qiagen, Germany. Also here, the significant decrease in
total methylation (over all 8CpG sites) was documented in
Figure 8(d). Each CpG site showed decreased methylation
level that was less strong as observed for the pyrosequencing
with the LINE1 element kit from Qiagen, Germany, and
Line1 CpG1-6.Aswell,thedecreaseintheLINE1methylation
was different in each CpG site; a fact that might underline
that specific CpG sites could be preferentially targeted by the
epigenetic regulators (chemicals and drugs).
4. Discussion
Toxic agents that are not mutagenic could cause stable
adversephenotypicchangesiftheyinterferedwithepigenetic
processes. DNA methylation in regulatory regions such as
promoters and enhancers could silence gene expression, and
an inverse correlation between gene expression and DNA8 BioMed Research International
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Figure 7: Assessment of HACAT cells methylation after in vitro chemical treatment using the self-designed assays (PSQ primer design,
Qiagen, Germany). HACAT cells were treated in vitro with DNA demethylating agent 5-aza-2
򸀠-deoxycytidine (A) (1𝜇Mf o r7 2h )a n dt h e
histone deacetylase inhibitor trichostatin A (T2) (1𝜇M for 36h).
methylationinpromoterswasproposed.TheprocessofDNA
methylation has therapeutic and toxic implications. Agents
thatinterferewithDNAmethylationprocessescouldbeused
toremovedeleteriousDNAmethylationtherapeuticallyoron
the other hand could introduce DNA methylation aberration
with toxic consequences. Nevertheless, DNA methylation
inhibitors were introduced into clinical practice for anti-
cancer treatments [9, 20].
4.1. Assessment of DNA Methylation as Toxicological Evi-
dence. Adversehealtheffectsinducedinhumansuponexpo-
sure to environmental components (particulate matter and
ozone) and pollutants (arsenic, cadmium, bisphenol A, and
paraquat) might cause changes the epigenome [3, 15, 16, 23,
24]). Thus, epigenetics is an important mechanism in the
ability of environmental chemicals to influence health and
disease [3].
In this paper it is shown that LINE1 element can be used
as indicator not only for epigenetic modifying chemicals for
global methylation but also for focal methylation. Commer-
cialavailablekitsandself-designedassayscanbeused.Invitro
available and established cell lines are suitable for investiga-
tionofstressorsthataffectDNAmethylationwhileepigenetic
modifying drugs are able to change the methylation profiles
in vitro. These findings are supported by previous publica-
tions such as that of Tabish et al., 2012, that shows the global
DNA methylation changes in human lymphoblastoid (TK6)
cells (in vitro)i nr e s p o n s et o5d i r e c ta n d1 0i n d i r e c t - a c t i n g
genotoxic agents. The authors show the effect of exposure
of 5-methyl-2
򸀠-deoxycytidine between control and exposed
cultures but also to benzene, hydroquinone, styrene, carbon
tetrachloride, and trichloroethylene and they concluded that
changes in global DNA methylation are an early event in
response to agents traditionally considered as genotoxic [17].
4.2. Assessment of DNA Methylation in Clinical Practice.
Modification in DNA methylation could be used as indicator
forincreasedoccupationalriskinworkers.Hintsinthisdirec-
tionwasgiveninarecentstudyofGodderisetal.,2012,where
it was found that global DNA hypermethylation was found
in the lymphocytes of solvent-exposed worker population
compared with the referents (𝑃 = 0.001, 𝑟 = −0.544)a n dw a s
negatively associated with the exposure [25]. Furthermore,
D N Am e t h y l a t i o nc o u l db eu s e da se a r l ym a r k e ri nt h e
development of serious diseases such as cancer [26]a n d
Parkinson’s disease [24]. Additionally, it could be used in
clinical diagnostics: emerging research demonstrates that
DNA methylation is responsible for cellular differentiationBioMed Research International 9
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Figure 8: Assessment of HACAT cells methylation after in vitro chemical treatment using LINE1 element kit (Qiagen, Germany). HACAT
cells were treated in vitro with DNA demethylating agent 5-aza-2
򸀠-deoxycytidine (A) (1𝜇M for 72h) and the histone deacetylase inhibitor
trichostatin A (T2) (1𝜇M for 36h).
and, when measured in whole peripheral blood, serves not
only to distinguish cancer cases from controls [26]b u ta l s o
to distinguish between the drug sensitive and drug resistant
cells.
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